Our results suggest that IBD patients harboring risk alleles that sensitize the epithelial barrier to apoptosis may be more likely to respond to anti-TNF therapies, and if confirmed, this could lead to more efficient deployment of such treatments. Here, TNF is linked to inflammatory bowel disease.